Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow: 2013-2024

Historic Net Cash Flow for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$3.2 million.

  • Viridian Therapeutics, Inc.\DE's Net Cash Flow fell 43.53% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.7 million, marking a year-over-year decrease of 134.57%. This contributed to the annual value of -$3.2 million for FY2024, which is 93.87% up from last year.
  • Viridian Therapeutics, Inc.\DE's Net Cash Flow amounted to -$3.2 million in FY2024, which was up 93.87% from -$52.8 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Net Cash Flow ranged from a high of $113.3 million in FY2022 and a low of -$52.8 million during FY2023.
  • Its 3-year average for Net Cash Flow is $19.1 million, with a median of -$3.2 million in 2024.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Net Cash Flow soared by 3,248.42% in 2022 and then crashed by 146.57% in 2023.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Net Cash Flow stood at $21.1 million in 2020, then plummeted by 117.09% to -$3.6 million in 2021, then spiked by 3,248.42% to $113.3 million in 2022, then slumped by 146.57% to -$52.8 million in 2023, then spiked by 93.87% to -$3.2 million in 2024.